{"schema_version":"secwatch.filing_event.v1","accession":"0001082554-23-000014","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.883381+00:00","generated_at":"2026-06-16T00:08:13.863005+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"United Therapeutics Q1 revenue $506.9M (+10% YoY); Tyvaso sales up 39%","bullets":["Net income $240.9M flat YoY; diluted EPS $4.86 vs $5.03.","Tyvaso franchise net sales $238.4M (+39%) driven by Tyvaso DPI launch and label expansion.","Treprostinil products grew 16% combined; Orenitram hit record revenue of $88.2M.","R&D expense rose 20% to $82.9M, primarily on TETON IPF studies.","Effective tax rate decreased to 17% from 22% due to excess share-based compensation benefits."],"urls":{"canonical":"https://secwatch.observer/filing/0001082554-23-000014","json":"https://secwatch.observer/filing/0001082554-23-000014.json","markdown":"https://secwatch.observer/filing/0001082554-23-000014.md","text":"https://secwatch.observer/filing/0001082554-23-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000108255423000014/0001082554-23-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000108255423000014/uthr-20230503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T00:08:13.863005+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fa5533f31693118bc06e76b6d89c47de350e022e","claim":"UNITED THERAPEUTICS Corp reported quarter ended March 31, 2023 results: revenue $506.9 million, net income $240.9 million, EPS $4.86 per diluted share.","evidence_excerpt":"Total revenues in the first quarter of 2023 grew 10% year-over-year to $506.9 million, compared to $461.9 million in the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1082554/000108255423000014/0001082554-23-000014-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2023"},{"label":"Revenue","value":"$506.9 million"},{"label":"Net income","value":"$240.9 million"},{"label":"EPS","value":"$4.86 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}